Skip to main content

Home/ Stock Market Traders/ Group items tagged biotechnology

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Brian Plain

Human Genome Could Be Takeover Target of Multiple Big Pharma Players - 0 views

www.stockmarketfunding.com/...keover-Target-of-Multiple.aspx

hgsi jnj pfe human genome sciences takeover buyout target biotechnology fda GlaxoSmithKline gsk Benlysta

shared by Brian Plain on 17 Nov 10 - No Cached
  • Brian Plain on 17 Nov 10
     
    StockMarketFunding.com reports that Human Genome Sciences FDA Panel Recommendation for Benlysta may cause many large biotechnology players to look at HGSI as a takeover target.
Brian Plain

Human Genome Sciences Benlysta FDA Drug Approval for Lupus Patients - 0 views

www.stockmarketfunding.com/...lysta-Drug-Approval-Lupus.aspx

Human Genome Sciences Benlysta hgsi drug approval commentary radio stock lupis patients trading new

shared by Brian Plain on 11 Nov 10 - No Cached
  • Brian Plain on 11 Nov 10
     
    Human Genome Sciences Benlysta FDA Drug Approval for Lupus Patients. Human Genome Sciences HGSI Special Biotech Future Video. SMF Reiterates Strong Buy Rating on Human Genome
Brian Plain

DNDN Options Trading Dendreon FDA has approved PROVENGE Stock Trading Video - 1 views

www.stockmarketfunding.com/...FDA-has-approved-PROVENGE.aspx

DNDN Options trading FDA approval Dendreon

shared by Brian Plain on 30 Apr 10 - Cached
  • Brian Plain on 30 Apr 10
     
    Dendreon Provenge Approval Call Summary (45.50 +5.88) -Update : During the call, the co said that it will provide Provenge to 2000 patients in next 12 months. Co said that demand for Provenge will exceed co's ability to provide it in the first 12 months; will continue build out of manufacturing capabilities. Mgmt said that 1 infusion will cost $31k; complete course will cost $93k. and EPS of $1.65.
1 - 3 of 3
Showing 20▼ items per page